Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer?
作者信息
Martin John D, Duda Dan G, Jain Rakesh K
机构信息
From NanoCarrier Co, Ltd, Kashiwa, Chiba, Japan (J.D.M.).
the Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (D.G.D., R.K.J.).
出版信息
Circ Res. 2020 Aug 28;127(6):724-726. doi: 10.1161/CIRCRESAHA.120.317720. Epub 2020 Aug 27.
Abstract
摘要
相似文献
1
Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer?超越VEGF通路抑制的抗血管生成癌症治疗：PP2A/B55α复合物的抑制是答案吗？
Circ Res. 2020 Aug 28;127(6):724-726. doi: 10.1161/CIRCRESAHA.120.317720. Epub 2020 Aug 27.
2
B55α/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling: A Complementary Approach To Disrupt Pathological Vessels?B55α/PP2A在血管重塑过程中限制内皮细胞凋亡：一种破坏病理性血管的补充方法？
Circ Res. 2020 Aug 28;127(6):707-723. doi: 10.1161/CIRCRESAHA.119.316071. Epub 2020 Jun 12.
3
PHD2 Targeting Overcomes Breast Cancer Cell Death upon Glucose Starvation in a PP2A/B55α-Mediated Manner.靶向PHD2通过PP2A/B55α介导的方式克服葡萄糖饥饿诱导的乳腺癌细胞死亡。
Cell Rep. 2017 Mar 21;18(12):2836-2844. doi: 10.1016/j.celrep.2017.02.081.
4
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.在抑制VEGF信号传导后，正常毛细血管发生退化过程中的细胞变化。
Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H547-59. doi: 10.1152/ajpheart.00616.2005. Epub 2005 Sep 19.
5
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.癌症治疗中针对血管生成：超越血管内皮生长因子
Oncologist. 2015 Jun;20(6):660-73. doi: 10.1634/theoncologist.2014-0465. Epub 2015 May 22.
6
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.缺氧诱导因子-1靶基因作为肿瘤血管对血管内皮生长因子抑制反应的指标
Cancer Res. 2008 Mar 15;68(6):1872-80. doi: 10.1158/0008-5472.CAN-07-1589.
7
Docosahexaenoic acid inhibits vascular endothelial growth factor (VEGF)-induced cell migration via the GPR120/PP2A/ERK1/2/eNOS signaling pathway in human umbilical vein endothelial cells.二十二碳六烯酸通过 GPR120/PP2A/ERK1/2/eNOS 信号通路抑制人脐静脉内皮细胞中血管内皮生长因子（VEGF）诱导的细胞迁移。
J Agric Food Chem. 2014 May 7;62(18):4152-8. doi: 10.1021/jf5007165. Epub 2014 Apr 24.
8
Endostatin down-regulates soluble guanylate cyclase (sGC) in endothelial cells in vivo: influence of endostatin on vascular endothelial growth factor (VEGF) signaling.内皮抑素在体内下调内皮细胞中的可溶性鸟苷酸环化酶（sGC）：内皮抑素对血管内皮生长因子（VEGF）信号传导的影响。
Endothelium. 2005 Sep-Dec;12(5-6):251-7. doi: 10.1080/10623320500476690.
9
Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis.抑制蛋白磷酸酶 2A 通过 HIF-1α-VEGF 介导的血管生成增加药物灌注，从而使胰腺癌对化疗敏感。
Cancer Lett. 2014 Dec 28;355(2):281-7. doi: 10.1016/j.canlet.2014.09.048. Epub 2014 Oct 7.
10
LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.LB100，一种具有强大化学增敏和放射增敏潜力的PP2A小分子抑制剂。
Cancer Biol Ther. 2015;16(6):821-33. doi: 10.1080/15384047.2015.1040961. Epub 2015 Apr 21.
引用本文的文献
1
Vascular Patterning as Integrative Readout of Complex Molecular and Physiological Signaling by VESsel GENeration Analysis.血管模式形成作为血管生成分析对复杂分子和生理信号的综合解读。
J Vasc Res. 2021;58(4):207-230. doi: 10.1159/000514211. Epub 2021 Apr 9.
本文引用的文献
1
B55α/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling: A Complementary Approach To Disrupt Pathological Vessels?B55α/PP2A在血管重塑过程中限制内皮细胞凋亡：一种破坏病理性血管的补充方法？
Circ Res. 2020 Aug 28;127(6):707-723. doi: 10.1161/CIRCRESAHA.119.316071. Epub 2020 Jun 12.
2
Combining microenvironment normalization strategies to improve cancer immunotherapy.联合微环境正常化策略以提高癌症免疫治疗效果。
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3728-3737. doi: 10.1073/pnas.1919764117. Epub 2020 Feb 3.
3
Vessel co-option in glioblastoma: emerging insights and opportunities.血管生成拟态在胶质母细胞瘤中的作用：新的认识和机遇。
Angiogenesis. 2020 Feb;23(1):9-16. doi: 10.1007/s10456-019-09691-z. Epub 2019 Nov 2.
4
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.双重程序性死亡受体 1 和血管内皮生长因子受体 2 阻断促进肝癌血管正常化并增强抗肿瘤免疫反应。
Hepatology. 2020 Apr;71(4):1247-1261. doi: 10.1002/hep.30889. Epub 2019 Oct 14.
5
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges.肿瘤血管正常化功能：进展、机遇与挑战。
Annu Rev Physiol. 2019 Feb 10;81:505-534. doi: 10.1146/annurev-physiol-020518-114700.
6
Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies.实验和计算分析揭示了肿瘤血管选择的动力学和最佳治疗策略。
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2662-2671. doi: 10.1073/pnas.1818322116. Epub 2019 Jan 30.
7
Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.当与 PD-1 阻断联合使用时，蛋白磷酸酶-2A 的药理学抑制可实现持久的免疫介导的抗肿瘤活性。
Nat Commun. 2018 May 29;9(1):2126. doi: 10.1038/s41467-018-04425-z.
8
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.利用抗血管生成药物增强癌症免疫治疗：机遇与挑战。
Nat Rev Clin Oncol. 2018 May;15(5):325-340. doi: 10.1038/nrclinonc.2018.29. Epub 2018 Mar 6.
9
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.血管密度和标准化在乳腺癌患者新辅助贝伐单抗和化疗反应中的作用。
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14325-30. doi: 10.1073/pnas.1518808112. Epub 2015 Nov 2.
10
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.卡铂和纳米白蛋白结合型紫杉醇抗VEGF治疗后肿瘤血管生成改善与肺癌患者生存率相关。
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1547-52. doi: 10.1073/pnas.1424024112. Epub 2015 Jan 20.
Zotero 插件